<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00206531</url>
  </required_header>
  <id_info>
    <org_study_id>114/05</org_study_id>
    <nct_id>NCT00206531</nct_id>
  </id_info>
  <brief_title>The Role of Naive T-Cells in HIV Pathogenesis</brief_title>
  <official_title>Role of Naive T-Cells in the Pathogenesis of T-Cell Decline and Long Term Persistence of HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayside Health</source>
  <brief_summary>
    <textblock>
      While HIV mainly infects mature T-cells it can also infect newly produced (or naïve) T-cells.&#xD;
      These infected naïve T cells may then act a viral reservoir even in patients with&#xD;
      undetectable viral loads. Understanding when and how these cells are infected is important&#xD;
      because it could help us to understand why patients fail therapy even if they have a&#xD;
      persistently undetectable viral load.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of this project is to provide a comprehensive analysis of the role of naïve&#xD;
      T-cells in the pathogenesis of T-cell decline and long-term persistence of HIV infection.&#xD;
&#xD;
      The study is divided into two parts.&#xD;
&#xD;
      Part 1 aims to determine the origin of HIV infected naïve T-cells in vivo by assessing the&#xD;
      viral relatedness between HIV strains from naïve and memory CD4 T-cells. To do this we will&#xD;
      be studying ten chronically infected individuals. Naïve and memory CD4 T-cells from these&#xD;
      individuals will be purified using a magnetic bead sorting (MACS) strategy. Envelope&#xD;
      sequences will then be isolated and subjected to diversity calculation&#xD;
&#xD;
      Part 2 seeks to answer whether infection of naïve T-cells is established early in infection&#xD;
      and what the effect of antiretroviral therapy is on this subset of T-cells. We will initially&#xD;
      examine the relative proportion of CD31+ (recent thymic emigrants) and CD31- naive CD4+&#xD;
      T-cells in infected acute (n=15) and chronic (n=15) infection and uninfected (n=15)&#xD;
      individuals compared with healthy controls. We will then prospectively test individuals prior&#xD;
      to and at 3, 6, 12, 18 and 24 months following intiation of HAART (Highly Active&#xD;
      Antiretroviral Therapy) in individuals with acute (n=10) and chronic (n=10) HIV infection.&#xD;
      Immunophenotyping will detemine the proportion of naïve T-cells that are CD31+ and those that&#xD;
      are CD31-. Naïve and memory T-cell subsets will again be purified and total and integrated&#xD;
      HIV DNA will be quantified using real-time PCR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>75</enrollment>
  <condition>HIV Infections</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
        - HIV positive by ELISA and Western Blot VL &gt;2,000, CD4 &gt;350&#xD;
&#xD;
        Part 2:&#xD;
&#xD;
          -  HIV positive by ELISA and Western Blot&#xD;
&#xD;
          -  Established Chronic infection (15 individuals)&#xD;
&#xD;
          -  Acute infection (15 individuals).&#xD;
&#xD;
          -  Any viral load or CD4 count.&#xD;
&#xD;
          -  No therapy.&#xD;
&#xD;
          -  Any individual who initiates HAART as determined by the treating physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon R Lewin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Infectious Diseases Unit, The Alfred Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jenny Hoy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head Clinical Research Unit, Infectious Diseases Unit, Alfred Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon R Lewin</last_name>
    <phone>+61 3 9276 3009</phone>
    <email>S.Lewin@alfred.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon R Lewin</last_name>
      <phone>+61 3 9276 3009</phone>
      <email>S.Lewin@alfred.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>October 3, 2006</last_update_submitted>
  <last_update_submitted_qc>October 3, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2006</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Naive T-cells</keyword>
  <keyword>CD31</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

